We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adamas Pharmaceuticals Inc | NASDAQ:ADMS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.22 | 9.33 | 8.30 | 0 | 01:00:00 |
|
|
|
Delaware
|
|
42-1560076
|
(State or other jurisdiction of Incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☒
|
Non-accelerated filer
|
☐ (Do not check if a smaller reporting company)
|
Smaller reporting company
|
☐
|
|
|
Emerging growth company
|
☒
|
|
|
|
|
|
|
Title of Securities
to be Registered
|
Amount to be
Registered(1)
|
Proposed
Maximum
Offering Price
per Share(3)
|
Proposed
Maximum
Aggregate
Offering Price
|
Amount of
Registration
Fee
|
Common Stock, par value $0.001 per share, reserved for issuance pursuant to the 2014 Equity Incentive Plan
|
932,822(2)
|
$29.22
|
$27,257,059
|
$3,394
|
Common Stock, par value $0.001 per share, reserved for issuance pursuant to the 2014 Employee Stock Purchase Plan
|
233,206(2)
|
$29.22
|
$6,814,279
|
$848
|
Common Stock, par value $0.001 per share, reserved for issuance pursuant to the 2016 Inducement Plan
|
450,000
|
$29.22
|
$13,149,000
|
$1,637
|
Total
|
1,616,028
|
|
$47,220,338
|
$5,879
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock of Adamas Pharmaceuticals, Inc. (the “Registrant”) that become issuable under the 2014 Equity Incentive Plan (the “2014 EIP”), the 2014 Employee Stock Purchase Plan (the “2014 ESPP”), and the 2016 Inducement Plan (the “2016 Plan) set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant’s common stock.
|
(2)
|
Represents additional shares of the Registrant’s common stock reserved for future issuance under the 2014 EIP and 2014 ESPP by reason of the automatic increase provision of the 2014 EIP and 2014 ESPP.
|
(3)
|
Estimated in accordance with Rule 457(h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of
$29.22
, the average of the high and low prices of the Registrant’s common stock as reported on The NASDAQ Global Market on
February 20, 2018
.
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
Amended and Restated Certificate of Incorporation of Adamas Pharmaceuticals, Inc.
|
|
|
|
|
|
Amended and Restated Bylaws of Adamas Pharmaceuticals, Inc.
|
|
|
|
|
|
Form of Common Stock Certificate of Adamas Pharmaceuticals, Inc.
|
|
|
|
|
|
Opinion of Cooley LLP.
|
|
|
|
|
|
Consent of Independent Registered Public Accounting Firm.
|
|
|
|
|
|
Consent of Cooley LLP (included in Exhibit 5.1).
|
|
|
|
|
|
Power of Attorney (included on the signature page of this Form S-8).
|
|
|
|
|
|
Adamas Pharmaceuticals, Inc. 2014 Equity Incentive Plan.
|
|
|
|
|
|
Form of Stock Option Grant Notice and Option Agreement under the Adamas Pharmaceuticals, Inc. 2014 Equity Incentive Plan.
|
|
|
|
|
|
Form of Restricted Stock Unit Agreement and Grant Notice under the Adamas Pharmaceuticals, Inc. 2014 Equity Incentive Plan.
|
|
|
|
|
|
Adamas Pharmaceuticals, Inc. 2014 Employee Stock Purchase Plan.
|
|
|
|
|
|
Adamas Pharmaceuticals, Inc. Amended and Restated 2016 Inducement Plan.
|
|
|
|
|
|
Form of Restricted Stock Unit Grant Notice and Award Agreement under the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan.
|
|
|
|
|
|
Form of Stock Option Grant Notice and Option Agreement under the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan.
|
|
|
ADAMAS PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Gregory T. Went
|
|
|
|
Gregory T. Went, Ph.D.
|
|
|
|
Chief Executive Officer and Chairman
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Gregory T. Went
|
|
Chief Executive Officer and Chairman
|
|
February 22, 2018
|
Gregory T. Went, Ph.D.
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Alfred G. Merriweather
|
|
Chief Financial Officer
|
|
February 22, 2018
|
Alfred G. Merriweather
|
|
(Principal Financial Officer)
|
|
|
|
|
|
|
|
/s/ Christopher B. Prentiss
|
|
Chief Accounting Officer
|
|
February 22, 2018
|
Christopher B. Prentiss
|
|
(Principal Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Michael Bigham
|
|
Director
|
|
February 22, 2018
|
Michael Bigham
|
|
|
|
|
|
|
|
|
|
/s/ Martha J. Demski
|
|
Director
|
|
February 22, 2018
|
Martha J. Demski
|
|
|
|
|
|
|
|
|
|
/s/ Mardi C. Dier
|
|
Director
|
|
February 22, 2018
|
Mardi C. Dier
|
|
|
|
|
|
|
|
|
|
/s/ William Ericson
|
|
Director
|
|
February 22, 2018
|
William Ericson
|
|
|
|
|
|
|
|
|
|
/s/ Ivan Lieberburg
|
|
Director
|
|
February 22, 2018
|
Ivan Lieberburg, M.D., Ph.D.
|
|
|
|
|
|
|
|
|
|
/s/ John MacPhee
|
|
Director
|
|
February 22, 2018
|
John MacPhee
|
|
|
|
|
|
|
|
|
|
/s/ David L. Mahoney
|
|
Director
|
|
February 22, 2018
|
David L. Mahoney
|
|
|
|
|
1 Year Adamas Pharmaceuticals Chart |
1 Month Adamas Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions